Yutong Zhong
Business Development Manager Areterna
Seminars
Tuesday 21st July 2026
Redefining In Vivo CAR-T: From Concept to Clinic
4:15 pm
- Showcasing a CD8 antibody-conjugated LNP platform delivering CD19 CAR mRNA with unprecedented specificity and efficiency
- Demonstrating how our proprietary ionizable lipids and antibody conjugation technologies achieve >90% CD8⁺ T cell transfection in humanized models
- Highlighting rapid and sustained B cell clearance after a single dose, robust safety profile in non-human primates and scalable GMP manufacturing with a clear path to the clinic
